Status report of lipid-lowering trials in diabetes.
The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes. Diabetic dyslipidaemia is an important risk factor and is open to therapeutic intervention. However, as yet there are no primary or secondary coronary heart disease prevention trials of lipid-lowering therapy reported in diabetic populations. In this review, on-going clinical trials of lipid-lowering therapy in specific diabetic populations will be described.
Betteridge
D J
DJ
Department of Medicine, University College, London, UK. j.betteridge@ucl.ac.uk
Colhoun
H
H
Armitage
J
J
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000517:prevention & control; D000069059:Atorvastatin; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control* / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D011345:Fenofibrate / Q000627:therapeutic use; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012307:Risk Factors
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D011758:Pyrroles; D000069059:Atorvastatin; D011345:Fenofibrate